ArticleAntibodies (Basel, Switzerland)2026

Clinical Characteristics and Risk Factors for Severe Immune-Related Liver Injury Following Nivolumab and Ipilimumab Combination Therapy.

Yuichi Yamazaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.